Key clinical point: Patients with a high bleeding risk could safely receive dual-antiplatelet therapy for just 1 month following placement of Onyx coronary stents.
Major finding: Cardiac death or MI occurred in 7.0% of patients in months 1-12, a statistically significant difference below the 9.7% performance goal.
Study details: Onyx ONE Clear, a single-arm, multicenter study with 1,506 patients.
Disclosures: Onyx ONE and Onyx ONE Clear were sponsored by Medtronic. Dr. Kirtane’s institution has received research support from Medtronic, and from Abbott Vascular, Abiomed, Boston Scientific, Cathworks, CSI, Philips, ReCor Medical, and Siemens.
Kirtane AJ et al. ACC 2020, Abstract 903-06.